15 minutes. Please correct me if I missed this. I did not hear the CEO say, in this weeks presentation, that the IMEXF excelerated dye process reduces pre scope prep from an hour to 15 minutes. Is this still on the table as a primary benefit of the system? If a urologist can cut his procedure turn-around they might be able to increase the number of procedures they do. In my area you have to wait a while to see a urologist, so this could speed up accurate diagnosis for many anxious people while improving the Uroligist's profitability. 1) Jim hit the IMEXF advantage of not having to switch between scope images pretty hard. 2) I heard him elude to the promise that bladder cancer is just a starting point with multiple flat cancers as potential target markets. 3) He basically also said IMEXF is for sale. All three of those are good, but there has not been an immediate rush to buy the stock since he delivered his pitch. US volume has been low lately. Also note that IMEXF has not had a conference call Q and A for shareholders as was proposed for January by Kilmer Lucas. I understand that a lot of resources went into prepping for this weeks conference and this could have bumped the conference call. I am hopeful that conference call is still on the table. My last point: when estimates are made for the size of a market, isn't that for annual sales? So, let's say a $40 billion (in USD) annual world market could easily grow into over a half a trillion dollar decade market. Potential buyout prospects are going to value what the technology's potential share of the market is over a decade or more, not just its first year's sale potential.
